Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride
S Vrignaud, J Hureaux, S Wack, JP Benoit… - International journal of …, 2012 - Elsevier
Erlotinib hydrochloride (ERLO) belongs to the tyrosine kinase inhibitor family and is used for
the treatment of pancreatic cancers. In the present study, ERLO was entrapped in lipid …
the treatment of pancreatic cancers. In the present study, ERLO was entrapped in lipid …
Co-Delivery of erlotinib and resveratrol via nanostructured lipid Carriers: a synergistically promising approach for cell proliferation prevention and ROS-Mediated …
L Asadollahi, A Mahoutforoush, SS Dorreyatim… - International Journal of …, 2022 - Elsevier
Cancer treatments are always associated with various challenges, and scientists are
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …
constantly trying to find new therapies and methods. Erlotinib (ELT) is a well-known …
Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
Epidermal growth factor receptor variant III (EGFRvIII) is the most common variant of the EGF
receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus …
receptor in many human tumors. This variant is tumor specific and highly immunogenic, thus …
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
ML Bondì, A Azzolina, EF Craparo, C Botto… - Journal of …, 2014 - Springer
Background In hepatocellular carcinoma (HCC), different signaling pathways are de-
regulated, and among them, the expression of the epidermal growth factor receptor (EGFR) …
regulated, and among them, the expression of the epidermal growth factor receptor (EGFR) …
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells
ML Bondì, C Botto, E Amore, MR Emma… - International journal of …, 2015 - Elsevier
Here, the potential of two nanostructured lipid carriers (NLC) for controlled release of
sorafenib was evaluated. The obtained systems showed characteristics suitable as drug …
sorafenib was evaluated. The obtained systems showed characteristics suitable as drug …
Cancer chemotherapy with lipid-based nanocarriers
D Liu, N Zhang - Critical Reviews™ in Therapeutic Drug …, 2010 - dl.begellhouse.com
Nanotechnology has a profound effect on many areas of scientific research. Having grown
exponentially, the focus of nanotechnology has been on therapeutic activity, such as cancer …
exponentially, the focus of nanotechnology has been on therapeutic activity, such as cancer …
Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations
H Xu, C He, Y Liu, J Jiang, T Ma - Artificial cells, nanomedicine …, 2018 - Taylor & Francis
The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung
cancer. The liposomes were prepared by using solvent evaporation method. Various …
cancer. The liposomes were prepared by using solvent evaporation method. Various …
Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro
NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and
surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle …
surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle …
Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl
R Rampaka, K Ommi, N Chella - Journal of Drug Delivery Science and …, 2021 - Elsevier
Abstract Background and objectives Erlotinib HCl is approved for the treatment of metastatic
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
non-small cell lung cancer. Owing to its poor aqueous solubility and presystemic …
Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver
Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in non-small cell
lung cancer is further researched for eventual liver cancer treatment. However, conventional …
lung cancer is further researched for eventual liver cancer treatment. However, conventional …